There has been plenty of press about the issues of whether coated stents made by Boston Scientific (BSX) and Johnson & Johnson (JNJ) can cause clotting problems. Several studies show that use of these stents by cardiologists has dropped sharply.
So has BSX stock price. The shares are down 15% over the last year.
But, the stent problems were not enough. A federal court has ruled that some of the product liability claims over heart defibrillators that the company’s Guidant unit made can proceed. "This case concerns the issues of whether, how, and to whom information was shared … about a device with an alleged defect," Judge Frank wrote in his ruling.
For BSX shareholders the bad news is that the company will have to continue to fight a two front war, and that usually does not come out well.
Douglas A. McIntyre
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
